JP2003520606A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003520606A5 JP2003520606A5 JP2001554422A JP2001554422A JP2003520606A5 JP 2003520606 A5 JP2003520606 A5 JP 2003520606A5 JP 2001554422 A JP2001554422 A JP 2001554422A JP 2001554422 A JP2001554422 A JP 2001554422A JP 2003520606 A5 JP2003520606 A5 JP 2003520606A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- hla
- seq
- restricted
- eso
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17900400P | 2000-01-28 | 2000-01-28 | |
| US60/179,004 | 2000-01-28 | ||
| US23710700P | 2000-09-29 | 2000-09-29 | |
| US60/237,107 | 2000-09-29 | ||
| PCT/US2001/002765 WO2001055393A2 (en) | 2000-01-28 | 2001-01-26 | Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011002419A Division JP5588363B2 (ja) | 2000-01-28 | 2011-01-07 | 癌抗原ｎｙｅｓｏ−１由来の新規ｍｈｃクラスｉｉ拘束ｔ細胞エピトープ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003520606A JP2003520606A (ja) | 2003-07-08 |
| JP2003520606A5 true JP2003520606A5 (https=) | 2008-03-13 |
| JP4776852B2 JP4776852B2 (ja) | 2011-09-21 |
Family
ID=26874905
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001554422A Expired - Fee Related JP4776852B2 (ja) | 2000-01-28 | 2001-01-26 | 癌抗原ｎｙｅｓｏ−１由来の新規ｍｈｃクラスｉｉ拘束ｔ細胞エピトープ |
| JP2011002419A Expired - Lifetime JP5588363B2 (ja) | 2000-01-28 | 2011-01-07 | 癌抗原ｎｙｅｓｏ−１由来の新規ｍｈｃクラスｉｉ拘束ｔ細胞エピトープ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011002419A Expired - Lifetime JP5588363B2 (ja) | 2000-01-28 | 2011-01-07 | 癌抗原ｎｙｅｓｏ−１由来の新規ｍｈｃクラスｉｉ拘束ｔ細胞エピトープ |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US7619057B2 (https=) |
| EP (4) | EP2333065B1 (https=) |
| JP (2) | JP4776852B2 (https=) |
| AU (1) | AU785151B2 (https=) |
| CA (1) | CA2398743C (https=) |
| WO (1) | WO2001055393A2 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001055393A2 (en) | 2000-01-28 | 2001-08-02 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1 |
| FR2830940B1 (fr) * | 2001-10-17 | 2007-06-15 | Commissariat Energie Atomique | Procede de selection de ligands d'hla-dp4 et ses applications |
| CN101024842A (zh) * | 2001-11-07 | 2007-08-29 | 曼康公司 | 编码靶相关抗原表位的表达载体及其设计方法 |
| EP1536021A1 (en) * | 2003-11-27 | 2005-06-01 | Consortium National de Recherche en Genomique (CNRG) | Method for HLA typing |
| US7632506B2 (en) * | 2004-09-09 | 2009-12-15 | Ludwig Institute For Cancer Research | Identification of new NY-ESO-1 epitopes recognized by CD4+ T-cells |
| WO2006133497A1 (en) * | 2005-06-15 | 2006-12-21 | Adelaide Research & Innovation Pty Ltd | Combination treatment |
| ES2709176T3 (es) | 2006-08-11 | 2019-04-15 | Life Sciences Res Partners Vzw | Péptidos inmunogénicos y su uso en trastornos inmunitarios |
| JP4305547B2 (ja) * | 2006-10-27 | 2009-07-29 | エプソンイメージングデバイス株式会社 | 実装構造体、電気光学装置、電子機器及び実装構造体の製造方法 |
| US7893533B2 (en) * | 2006-10-25 | 2011-02-22 | Epson Imaging Devices Corporation | Semiconductor device, mounting structure, electro-optical apparatus, electronic system, and method for manufacturing electronic component |
| EP2626081B1 (en) | 2008-02-14 | 2017-03-22 | Life Sciences Research Partners VZW | Immunogenic control of tumours and tumour cells |
| CN107252489A (zh) | 2009-04-13 | 2017-10-17 | 法国健康和医学研究院 | Hpv颗粒及其用途 |
| WO2011140284A2 (en) | 2010-05-04 | 2011-11-10 | Fred Hutchinson Cancer Research Center | Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses |
| HRP20171164T1 (hr) * | 2010-09-20 | 2017-10-20 | Biontech Cell & Gene Therapies Gmbh | Antigen-specifični t stanični receptori i t stanični epitopi |
| DE11787873T1 (de) | 2010-11-25 | 2013-12-12 | Imnate Sarl | Immugene Peptide zur Verwendung bei der Vorbeugung und/oder Behandlung von Infektionskrankheiten, Autoimmunerkrankungen, Immunreaktionen auf Allofaktoren, allergischen Erkrankungen, Tumoren, Transplantatabstossungen und Immunreaktionen auf virale Vektoren |
| GB201201511D0 (en) | 2012-01-30 | 2012-03-14 | Univ Leuven Kath | Modified epitopes for boosting CD4+ T-cell responses |
| EP3404111A1 (en) * | 2013-03-13 | 2018-11-21 | Health Research, Inc. | Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen |
| GB201309469D0 (en) | 2013-05-28 | 2013-07-10 | Imcyse Sa | Detection of CD4+ T lymphocytes |
| EP3604271A1 (en) * | 2013-06-28 | 2020-02-05 | Auckland Uniservices Limited | Peptides for amino acid and peptide conjugates and conjugation process |
| JP6406647B2 (ja) * | 2013-07-02 | 2018-10-17 | 公益財団法人がん研究会 | 細胞性免疫誘導ワクチン |
| GB201315946D0 (en) * | 2013-09-06 | 2013-10-23 | Immune Targeting Systems Its Ltd | Oncology vaccine |
| EP3046583B1 (en) | 2013-09-18 | 2019-02-13 | Aura Biosciences, Inc. | Virus-like particle conjugates for treatment of tumors |
| US10526391B2 (en) | 2014-07-22 | 2020-01-07 | The University Of Notre Dame Du Lac | Molecular constructs and uses thereof |
| GB201418433D0 (en) | 2014-10-17 | 2014-12-03 | Imcyse Sa | Novel immunogenic peptides |
| USD761957S1 (en) | 2014-11-11 | 2016-07-19 | Nuvasive, Inc. | Combined intradiscal insertion tool and intradiscal shim |
| CN107250103A (zh) | 2014-12-23 | 2017-10-13 | 玛格丽特·安妮·布林布尔 | 氨基酸缀合物和肽缀合物以及其用途 |
| WO2016128060A1 (en) * | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
| EP3067366A1 (en) * | 2015-03-13 | 2016-09-14 | Max-Delbrück-Centrum Für Molekulare Medizin | Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1 |
| US10729791B2 (en) | 2015-05-18 | 2020-08-04 | Imcyse Sa | Animal models for evaluating pharmaceutical compounds |
| GB2592821B (en) | 2015-07-31 | 2022-01-12 | Univ Minnesota | Modified cells and methods of therapy |
| MX2018004544A (es) | 2015-10-12 | 2018-11-09 | Nantomics Llc | Composiciones y métodos para los neoepítopos de cáncer viral. |
| JP2018532801A (ja) | 2015-10-30 | 2018-11-08 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 標的化がん療法 |
| TW201735952A (zh) | 2016-02-26 | 2017-10-16 | 瑪格蕾特 安 布萊博 | 胺基酸及肽共軛物以及共軛過程 |
| AU2017305396A1 (en) * | 2016-08-02 | 2019-02-21 | Nant Holdings Ip, Llc | Transfection of dendritic cells and methods therefor |
| CN110520530A (zh) | 2016-10-18 | 2019-11-29 | 明尼苏达大学董事会 | 肿瘤浸润性淋巴细胞和治疗方法 |
| IL269986B2 (en) | 2017-04-12 | 2024-06-01 | Aura Biosciences Inc | Targeted combination therapy |
| EP3634449A4 (en) | 2017-05-08 | 2021-03-17 | Gritstone Oncology, Inc. | ALPHAVIRUS NEOANTIGEN VECTORS |
| WO2018224166A1 (en) | 2017-06-09 | 2018-12-13 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy |
| EP3645021A4 (en) | 2017-06-30 | 2021-04-21 | Intima Bioscience, Inc. | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY |
| AU2019275072A1 (en) * | 2018-05-23 | 2021-01-21 | Seattle Project Corp. | Shared antigens |
| CN113710267B (zh) * | 2019-03-12 | 2025-05-09 | 生物技术公司 | 用于前列腺癌的治疗性rna |
| US20200318200A1 (en) * | 2019-04-02 | 2020-10-08 | The Brigham And Women's Hospital, Inc. | Methods for Identifying Progression of a Primary Melanoma |
| MX2021014525A (es) | 2019-05-30 | 2022-03-17 | Gritstone Bio Inc | Adenovirus modificados. |
| CN116438308A (zh) | 2020-08-06 | 2023-07-14 | 磨石生物公司 | 多表位疫苗盒 |
| CN116732078A (zh) * | 2023-07-21 | 2023-09-12 | 中国人民解放军海军军医大学 | 以pET28a作为载体制备肿瘤相关抗原NY-ESO-1的方法及应用 |
| US20250232833A1 (en) * | 2024-01-13 | 2025-07-17 | Noergaard Anders Kaare | Cyclin D1 Based Cancer Vaccine |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4870009A (en) | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
| US4738846A (en) | 1984-08-30 | 1988-04-19 | The Salk Institute For Biological Studies | Vaccine for vesicular stomatitis virus |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5175385A (en) | 1987-09-03 | 1992-12-29 | Ohio University/Edison Animal Biotechnolgy Center | Virus-resistant transgenic mice |
| US6723832B1 (en) | 1996-10-03 | 2004-04-20 | Ludwig Institute For Cancer Research | Isolated peptides corresponding to amino acid sequences of NY-ESO-1, which bind to MHC Class I and MHC Class II molecules, and uses thereof |
| AU4058489A (en) | 1988-08-08 | 1990-03-05 | Michael A. Iffiu | Collapsible recumbent bicycle with streamlined three-part folding canopy |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5175383A (en) | 1989-02-17 | 1992-12-29 | President And Fellows Of Harvard College | Animal model for benign prostatic disease |
| CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
| US5174986A (en) | 1989-07-05 | 1992-12-29 | Genpharm International, Inc. | Method for determining oncogenic potential of a chemical compound |
| US5840839A (en) * | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| US6287756B1 (en) * | 1997-05-05 | 2001-09-11 | Ludwig Institute For Cancer Research | Methods for determining presence of cancer in a sample by determining expression of an SSX gene |
| ES2281935T3 (es) * | 1997-10-08 | 2007-10-01 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Antigeno cancerigeno humano ny eso-1/ca6 y gen que codifica para el mismo. |
| JP2002506633A (ja) * | 1998-03-20 | 2002-03-05 | ジェンザイム・コーポレーション | Ｔ細胞応答を誘発するための遺伝子に基づくワクチンの組成物および使用法 |
| US6800730B1 (en) * | 1998-10-02 | 2004-10-05 | Ludwig Institute For Cancer Research | Isolated peptides which bind to MHC class II molecules, and uses thereof |
| JP4615805B2 (ja) | 1999-11-15 | 2011-01-19 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | Ｎｙ−ｅｓｏ−１ペプチド誘導体およびその使用 |
| WO2001055393A2 (en) | 2000-01-28 | 2001-08-02 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1 |
-
2001
- 2001-01-26 WO PCT/US2001/002765 patent/WO2001055393A2/en not_active Ceased
- 2001-01-26 US US10/182,506 patent/US7619057B2/en not_active Expired - Fee Related
- 2001-01-26 EP EP10010354.8A patent/EP2333065B1/en not_active Expired - Lifetime
- 2001-01-26 EP EP10010353A patent/EP2311950A1/en not_active Withdrawn
- 2001-01-26 CA CA2398743A patent/CA2398743C/en not_active Expired - Lifetime
- 2001-01-26 EP EP10010389A patent/EP2311951A1/en not_active Withdrawn
- 2001-01-26 EP EP01905152A patent/EP1252309A2/en not_active Withdrawn
- 2001-01-26 AU AU33062/01A patent/AU785151B2/en not_active Expired
- 2001-01-26 JP JP2001554422A patent/JP4776852B2/ja not_active Expired - Fee Related
-
2009
- 2009-09-28 US US12/568,134 patent/US8754046B2/en not_active Expired - Fee Related
-
2011
- 2011-01-07 JP JP2011002419A patent/JP5588363B2/ja not_active Expired - Lifetime
-
2014
- 2014-05-22 US US14/284,971 patent/US9447144B2/en not_active Expired - Fee Related
-
2016
- 2016-08-19 US US15/241,996 patent/US10251912B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003520606A5 (https=) | ||
| AU2008332278C1 (en) | Cancer vaccine composition | |
| JP5484734B2 (ja) | Ｈｌａ−ａ＊１１０１拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物 | |
| JP4235984B2 (ja) | Ｗｔ１特異的免疫療法のための組成物および方法 | |
| JP5393144B2 (ja) | Ｈｌａ−ａ＊３３０３拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物 | |
| US10617748B2 (en) | Immunogenic control of tumours and tumour cells | |
| Blake et al. | Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytes. | |
| JP4900884B2 (ja) | 腫瘍抗原 | |
| CA2480696C (fr) | Epitopes peptidiques communs a des antigenes d'une meme famille multigenique | |
| US20100015169A1 (en) | Tumor Antigens | |
| AU701531B2 (en) | Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor | |
| Vichier‐Guerre et al. | Induction of carbohydrate‐specific antibodies in HLA‐DR transgenic mice by a synthetic glycopeptide: a potential anti cancer vaccine for human use | |
| JP2003524016A (ja) | Ｈｌａ結合ペプチドおよびそれらの用途 | |
| JPH10511985A (ja) | ヒトグルタミン酸デカルボキシラーゼ（ｇａｄ）からの自己反応性ペプチド | |
| EP0994948B1 (fr) | Sequence nucleique du recepteur rii du tgfss, peptide code, et utilisations | |
| AU2013270496B2 (en) | Immunogenic control of tumours and tumour cells | |
| Marquardt et al. | Use of Combinatorial Peptide Libraries to Construct Functional Mimics of Tumor Epitopes Recognized by MHC Class I-Restricted Cytolytic T Lymphocytes By James Blake, Janet V. Johnston, Karl Erik Hellstrtm | |
| AU2016202443A1 (en) | Immunogenic control of tumours and tumour cells | |
| HK1188131A (en) | Immunogenic control of tumours and tumour cells |